Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary Shares by several executives on March 11, 2014, through the Company's ShareReward Plan. The transactions involved purchases at a price of 1670.89 pence per share. Participants included Sir Andrew Witty, Mr. S. Dingemans, Mr. S. M. Bicknell, Mr. R. G. Connor, Mr. D. S. Redfern, Ms. C. Thomas, Mr. P. C. Thomson, Dr. P. J. T. Vallance, Ms. E. Walmsley, and Mrs. V. A. Whyte. Acquisitions consisted of personal contributions matched by company contributions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1670.89 pence per Ordinary Share on March 11, 2014.
- Confirm the specific number of shares acquired by each listed executive under the ShareReward Plan.
- Review the total aggregate shareholding changes for the company's senior management team.